Kristin Haag

Aug 29, 2023 | acrjournals.onlinelibrary.wiley.com | Michelle Petri |Daniel Joyce |Kristin Haag |Andrea Fava

INTRODUCTION Both systemic lupus erythematosus (SLE) itself and the use of some immunosuppressants may impact the risk of COVID-19 (1-3). In particular, corticosteroids and B cell–depleting biologics such as rituximab impair vaccine response (4-6). SLE increases the risk of severe COVID-19 (hospitalization, intensive care unit stay, or intubation) both before and after vaccination (7).

Aug 17, 2023 | acrjournals.onlinelibrary.wiley.com | Michelle Petri |Daniel Joyce |Kristin Haag |Andrea Fava

No abstract is available for this article. Supporting Information Filename Description acr25109-sup-0001-Disclosureform.pdfPDF document, 1.8 MB Disclosure Form References 1, , , et al. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res (Hoboken) doi: https://doi.org/10.1002/acr.25094. 2023. E-pub ahead of print. 2, . COVID-19 in immunocompromised hosts: what we know so far.